ESG (Environmental, Social, and Governance) Data

| Environment | al | | | | | | | |
|-----------------|--|---------------------|--|---------------------|---------|---------|----------|---------|
| Promoting Env | vironmental Management | | | | | | | |
| Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | F | Y2021 |
| | 00 | | In Japan | t-CO ₂ | 152,486 | 130,572 | ✓ | 143,774 |
| | CO ₂ emissions | | Global | t-CO ₂ | 207,035 | 182,865 | ✓ | 191,399 |
| | | 0 | In Japan | t-CO ₂ | 78,597 | 69,103 | ✓ | 68,736 |
| CO_2 | | Scope 1*2 | Global | t-CO ₂ | 100,411 | 86,785 | ✓ | 88,249 |
| | CO ₂ emissions by Greenhouse Gas Protocol | Scope 2*2 | In Japan | t-CO ₂ | 73,889 | 61,468 | V | 75,038 |
| | | | Global | t-CO ₂ | 106,624 | 96,080 | √ | 103,150 |
| | | Scope 3, category 1 | In Japan | t-CO ₂ | 612,885 | 609,954 | V | 513,874 |
| | Total energy used*4 | | In Japan | 1,000GJ | 2,967 | 2,658 | ✓ | 2,818 |
| | | | Global | 1,000GJ | 3,853 | 3,710 | ✓ | 3,903 |
| Energy*3*5 | Electricity*5 | | Global | 1,000GJ | 2,040 | 1,976 | | 2,034 |
| | Renewable electricity | | Global | 1,000GJ | | 161 | | 210 |
| | Renewable electricity utilization rate*5 | | Global | % | _ | 7.5 | ✓ | 9.4 |
| \\/ata | Water consumed | | Global (Factories and research laboratories) | 1,000m ³ | 9,356 | 8,395 | ✓ | 8,486 |
| Water resources | Water discharged | Water discharged | | 1,000m³ | 9,111 | 8,113 | V | 8,464 |
| | Total amount of industrial waste, etc. discharged (outsourced waste treatment) | | Global (Factories and research laboratories) | t | 12,366 | 11,890 | V | 9,998 |
| Waste | Waste plastic recycling rate*6 | | Global (Factories and research laboratories) | % | _ | | V | 59.3 |
| | Disposal of hazardous waste*6 | · | Global (Factories and research laboratories) | t | | _ | ✓ | 4,350 |

[✓] Information with this mark is assured by KPMG AZSA Sustainability Co., Ltd.

| | uth of Employees | e and the Company | | | | | | | |
|-------------|-------------------------------|--|---------------|----------------|----------------|-------------------------|-------------------------|-----------------|--------------|
| Aspect | Classification | s and the Company Item | Sco | ope*1 | Unit | FY2019 | FY2020 | FV ⁴ | 2021 |
| Лоросс | Olassification | nem | In Japan | phe | Persons | 8,754 | 8,979 | ✓ | 9,13 |
| | | Number of employees by region | Outside Ja | nan | Persons | 6,594 | 7,054 | ✓ | 7,32 |
| | | Number of employees by region | Global | фин | Persons | 15,348 | 16,033 | ✓ | 16,45 |
| | | | In Japan | | Persons | 6,608 | 6,683 | | 6,75 |
| | | Number of male employees | Outside Ja | nan | Persons | 3,232 | 3,410 | | 3,50 |
| Frankrissa | | Number of male employees | Global | ιμαιι | | 9,840 | 10,093 | ∨ | 10,25 |
| | | | | | Persons | | | ✓ | |
| | | Northern (Courte and and | In Japan | | Persons | 2,146 | 2,296 | | 2,38 |
| | Employee dete*7 | Number of female employees | Outside Ja | apan | Persons | 3,362 | 3,644 | ✓ | 3,81 |
| Employees | Employee data*7 | | Global | Mala | Persons | 5,508 | 5,940 | ✓ | 6,20 |
| | | Average years of service | In Japan | Male Female | Years Years | 20.4 15.2 | 20.9 15.1 | | 21 15 |
| | | Average years or service | III Japaii | All | Years | 19.1 | 19.4 | | 19 |
| | | | | Male | Persons | 218 | 187 | | 16 |
| | | | | Female | Persons | 154 | 140 | | 13 |
| | | | In Japan | | | 372 | 327 | | 30 |
| | | New employees | | All | Persons | (non-consolidated: 236) | (non-consolidated: 211) | (non-cons | olidated: 15 |
| | | | Global | Male | Persons | 885 | 777 | | 76 |
| | | | | Female | Persons | 850 | 749 | | 84 |
| | | | | All | Persons | 1,735 | 1,526 | | 1,61 |
| | | | In Japan | | % | 24.5 | 25.6 | ✓ | 26 |
| | | Percentage of female employees | Outside Japan | | % | 51.0 | 51.7 | ✓ | 52 |
| | | | Global | | % | 35.9 | 37.0 | ✓ | 37. |
| | | | In Japan | | Persons | 213 | 235 | ✓ | 24 |
| | | | | | % | 7.3 | 7.9 | ✓ | 8. |
| | | | | | Persons | 1,097 | 1,258 | √ | 1,35 |
| | Diversity*7 | Female employees in managerial positions | Outside Ja | apan | % | 49 | 49 | V | 4 |
| | Diversity | | | | Persons | 1,310 | 1,493 | ✓ | 1,60 |
| Employees | | | Global | | % | 25.3 | 26.9 | ✓ | 28. |
| Litipioyees | | Percentage of female in senior managerial | In Japan | | % | 1.7 | 3.7 | | 4. |
| | | employees*8 | Global | | % | 22.8 | 16.3*9 | | 17. |
| | | Employment rate of people with physical or mental disabilities | In Japan | | % | 2.33 | 2.34 | ✓ | 2.3 |
| | | Positive response rate (%) on corporate culture & work environment through engagement survey | Global | | % | _ | _ | | 7 |
| | Lluman rangu | Amount of training/development investments per employee | Global | | Yen | _ | 96,186 | | 121,06 |
| | Human resource development | Turnover rate (due to personal reasons) | Global | | % | 5.3 | 4.1 | | 5 |
| | асторинент | Positive response rate (%) on development & growth opportunities through engagement survey | Global | | % | _ | _ | | 6 |
| | | growth opportunites through engagement survey | | | | | | | |

[✓] Information with this mark is assured by KPMG AZSA Sustainability Co., Ltd.

Mutual Growth of Employees and the Company

| | Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | FY | 2021 |
|--|-----------|--------------------------------|--|------------------|---------|--------|--------|----------|------|
| | Employees | Occupational health and safety | | In Japan | _ | 0.41 | 0.12 | ✓ | 0.17 |
| | | | Lost time injuries frequency rate*10 | Outside Japan*11 | _ | 2.56 | 2.09 | V | 2.31 |
| | | | | Global*11 | _ | 1.34 | 1.01 | ✓ | 1.11 |
| | | | Number of work-related casualties and injuries | Global | Persons | _ | 0 | ✓ | 0 |
| | | Labor union | Coverage of collective bergeining | In Japan | % | 100 | 100 | | 100 |
| | | | Coverage of collective bargaining | Global | % | 68 | 82 | | 88 |
| | | | | | | | | | |

✓ Information with this mark is assured by KPMG AZSA Sustainability Co., Ltd.

Enhancement of Communication with Stakeholders

| Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | FY2021 |
|--|---|--|----------|-------|-------------|-----------------|-----------------|
| Patients and medical professionals | Evaluation of corporate stance and MR activities | Overall assessment of MRs (all responding _physicians)*12 | In Japan | Rank | 1 st | 1 st | 1 st |
| | | Overall assessment of MRs (hospital doctors)*12 | In Japan | Rank | 1 st | 1 st | 1 st |
| | | Overall assessment of MRs (private-practice physicians)*12 | In Japan | Rank | 1 st | 1 st | 1 st |
| | Number of inquiries received by the product information center from outside the Company (prescription pharmaceutical) | | In Japan | Cases | 90,000 | 70,000 | 70,000 |

Improving Access to Healthcare

| Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | FY2021 |
|--------|---|---------------------------------|----------|---------|--------|--------|--------|
| Casial | Number of people who received breast cancer/cervical cancer screening | Aggregate (January to March) | In Nepal | Persons | _ | 186 | 1,091 |
| Social | Number of development projects conducted through the GHIT Fund*13 | Aggregate (January to December) | _ | Cases | 4 | 6 | 4 |

Social Contribution Activities

| Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | FY2021 |
|-----------|---|------|----------|--------------------|--------|--------|--------|
| Social | Amount of contributions | | In Japan | Millions of yen | 1,396 | 1,464 | 1,356 |
| Employees | Number of employees taking short- term volunteer leave | | In Japan | Persons | 16 | 0 | 11 |

| Governance | ; | | | | | | |
|------------|--|--|------------------|-----------------|--------|--------|--------|
| Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | FY2021 |
| | | Directors | Non-consolidated | Persons | 9 | 9 | 9 |
| | Structure of Board of Directors | Number of outside directors | Non-consolidated | Persons | 4 | 4 | 4 |
| | | Number of female directors | Non-consolidated | Persons | 1 | 1 | 1 |
| | | Number of Audit & Supervisory Board Members | Non-consolidated | Persons | 5 | 5 | 5 |
| Covernance | Ctrusture of Audit & Cuponisons Poord | Number of Outside Audit & Supervisory Board Members | Non-consolidated | Persons | 3 | 3 | 3 |
| Governance | Structure of Audit & Supervisory Board | Number of Outside Audit & Supervisory Board Members (female) | Non-consolidated | Persons | 2 | 2 | 2 |
| | Remuneration of Directors | Total | Non-consolidated | Millions of yen | 683 | 547 | 959 |
| | Remuneration of Audit & Supervisory Board Members | Total | Non-consolidated | Millions of yen | 120 | 120 | 154 |

Promoting Compliance Management

| Promoting C | ompliance ivianagement | | | | | | |
|-------------|---|---|------------------|---------|---------------|--------|---------------|
| Aspect | Classification | Item | Scope*1 | Unit | FY2019 | FY2020 | FY2021 |
| | Compliance training | Total | In Japan | Persons | 593 | 615 | 549 |
| | Training on Daiichi Sankyo Group | Number of employees participating in e-learning and | In Japan | Persons | 9,070 | 9,167 | 9,412 |
| | Individual Conduct Principles | group training | Outside Japan | Persons | Approx. 3,140 | 4,813 | Approx. 4,270 |
| | Corporate culture through an employee survey*6 | Positive response rate | Global | % | _ | _ | 84 |
| Compliance | Compliance Data | Number of allegations received | Global | Reports | 248 | 185 | 157 |
| Compliance | | Ratio of GVP-related employees undergoing training | Non-consolidated | % | 100 | 100 | 100 |
| | GVP*14 compliance training | Number of employees undergoing training for all employees | Non-consolidated | Persons | 5,822 | 5,849 | 5,873 |
| | Development-related training (including GCP) | Aggregate number of e-learning programs and group training sessions | Non-consolidated | Times | 92 | 141 | 127 |
| | Number of recalls (class I*15) | Number of recalls | Global | Reports | 0 | 0 | 0 |
| | | | | | 0 | 0 | |

- **I In Japan: Dalichi Sankyo (non-consolidated) and consolidated subsidiaries in Japan. Outside Japan: consolidated overseas subsidiaries. Global: Dalichi Sankyo (non-consolidated) and all its consolidated subsidiaries.

 **2 Scope 1: For sites in Japan, the emission factors stipulated by the Act on Promotion of Global Warming Countermeasures are used. The emissions from renewable energy and waste incineration are included. For overseas sites, the emission factors stipulated by the Act on Promotion of Global Warming Countermeasures are used. Scope 2: Generally, the emission factors are determined by the power contract or each country's regulations. If the specific factors are not available, the latest factors (as of 2019) published by the International Energy Agency (IEA) are used instead. The emissions from renewable energy are included.

 **3 The unit calorific values defined by the Act on the Rational Use of Energy are used to calculate the energy consumption of electricity and fuel.

 **4 Including renewable energy purchased externally and renewable energy used for on site power generation.

 **5 Starting in FY2020, the indicated values are divided between renewable energy derivatives and non-renewable energy derivatives.

 **6 Indicated starting in FY2021

- *7 The number of employees as of the settlement date of each Group company (as of March 31, 2022, for FY2021)
- *7 The number of employees as of the settlement date of each Group company (as of March 31, 2022, for FY2021) *8 Percentage of women who are in positions equivalent to division heads or higher positions *9 The definition of senior managerial employees in Group companies has been changed since FY2020. *10 Number of work-related deaths and injuries ÷ total number of hours actually worked × 1,000,000 The number of work-related deaths and injuries is calculated by counting the number of cases that involved at least a day of leave. *11 The overseas and global frequency rates for FY2019 to FY2020 were revised based on the revised total number of bours worked oursease.
- of hours worked overseas.
 *12 Conducted by ANTERIO Inc. (FY2019–FY2021)

- 12 Conducted by Anti-Hall Inc. (472 U1 +172 U21)
 13 Global Health Innovative Technology Fund
 14 Good Vigilance Practice: Standard for post-marketing safety control of pharmaceuticals, quasi-pharmaceutical products, cosmetics, and medical devices
 15 A situation where there is a reasonable probability that the use of or exposure to the product will severely affect the health or cause death



The Company updates its corporate website with other ESG data.

https://www.daiichisankyo.com/sustainability/performance-reports/esg/

105 Daiichi Sankyo Group Value Report 2022